Piper Jaffray Maintains an Overweight on XenoPort (XNPT); Price Target Increased
XNPT Hot Sheet
Rating Summary:1 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Piper Jaffray & Co. maintains an Overweight rating on XenoPort (Nasdaq: XNPT), price target increased from $26 to $30.
Piper analyst says, "Yesterday, XenoPort reported positive results from a Phase II study evaluating XP19986, a prodrug of the R-isomer of baclofen, in spinal cord injury (SCI) patients with spasticity. The rates of somnolence and dizziness were far lower than what is seen with conventional baclofen, suggesting an attractive point of differentiation. We would not be surprised if the next step is a pivotal study; we are modeling a 2012 launch. We are raising our price target to $30 from $26 on a slightly lower discount rate (14% from 15%) and higher spasticity sales estimates for '986 ($131 M by 2013).
To see more analyst ratings on XNPT Click Here.
XenoPort, Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs.
Piper analyst says, "Yesterday, XenoPort reported positive results from a Phase II study evaluating XP19986, a prodrug of the R-isomer of baclofen, in spinal cord injury (SCI) patients with spasticity. The rates of somnolence and dizziness were far lower than what is seen with conventional baclofen, suggesting an attractive point of differentiation. We would not be surprised if the next step is a pivotal study; we are modeling a 2012 launch. We are raising our price target to $30 from $26 on a slightly lower discount rate (14% from 15%) and higher spasticity sales estimates for '986 ($131 M by 2013).
To see more analyst ratings on XNPT Click Here.
XenoPort, Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs.
You May Also Be Interested In
- Nomura Securities Maintains a 'Neutral' on Tiffany & Co. (TIF); Cutting Estimates and Price Target
- Jefferies Slashes Price Target on Leap Wireless (LEAP)
- Barclays on U.S. Specialty Pharmaceuticals: Model Updates on FRX, MRX, WCRX & PCRX
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
